Amgen Stock Dips Despite Biotech Investment and Clinical Trial Success
Amgen's stock experienced a slight decline in after-hours trading on October 6, 2026, closing at EUR 356.18, which marked a 0.79% decrease from the prior close reported by Lang & Schwarz. The trading session saw a bid price of EUR 356.15 and an ask price of EUR 356.20, reflecting a EUR 2.85 drop from the previous close of EUR 359.03.
Beyond its stock performance, Amgen was highlighted as one of the investors in a $30 million biotech financing round. Arboretum LifeSciences, a Cambridge, Massachusetts-based company, launched with this Series A funding led by F-Prime, GV.406 Ventures, Hims & Hers, and Amgen. The company is developing an AI and genetic-testing platform aimed at supporting precision medicine and genomically stratified clinical research.
Michael Montalto, Amgen's vice president of Precision Medicine, noted that the platform could help expand access to molecular and clinical datasets for drug development. This investment underscores Amgen's commitment to advancing innovative technologies in the biotech sector.
Additionally, Amgen recently reported positive results from its Phase 3 OASIZ 301 study of dazodalibep in adults with moderate-to-severe systemic Sjögren's disease. The study met its primary endpoint, showing statistically significant and clinically meaningful improvement in systemic disease activity at Week 48, as measured by the EULAR Sjögren's Syndrome Disease Activity Index.